Literature DB >> 176935

Effect of cytosine arabinoside and 5-iodo-2'-deoxyuridine on a cytomegalovirus infection in newborn mice.

D K Kelsey, E R Kern, J C Overall, L A Glasgow.   

Abstract

Murine cytomegalovirus was inhibited by 0.6 to 1.2 mug of cytosine arabinoside per ml and by 0.3 to 0.6 mug of 5-iodo-2'-deoxyuridine in mouse embryo fibroblast cells. Human cytomegalovirus was inhibited by similar concentrations of the two drugs in WI-38 cells. Intraperitoneal inoculation of suckling mice with 10(4.5) plaque-forming units of murine cytomegalovirus provides a model for disseminated human cytomegalovirus infection in human newborn infants and is characterized by a widespread infection involving the liver, spleen, lung, kidney, and brain with a 70 to 90% mortality in 7 to 9 days. Treatment with 12.5 mg of cytosine arabinoside per kg or 25 mg of 5-iodo-2'-deoxyuridine per kg twice daily for 8 days had no effect on final mortality or the pathogenesis of the infection with the exception of reduced viral titers in the spleen of 5-iodo-2'-deoxyuridine-treated animals. These data indicate that neither cytosine arabinoside nor 5-iodo-2'-deoxyuridine are effective in the treatment of murine cytomegalovirus infections in suckling mice and suggest that they may be of limited value in the treatment of severe cytomegalovirus infections in human neonates.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 176935      PMCID: PMC429552          DOI: 10.1128/AAC.9.3.458

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  THE INCIDENCE OF INFECTION WITH CYTOMEGALOVIRUS IN A NORMAL POPULATION. A SEROLOGICAL STUDY IN GREATER LONDON.

Authors:  H STERN; S D ELEK
Journal:  J Hyg (Lond)       Date:  1965-03

2.  CELL CULTURE STUDIES ON ANTIVIRAL AGENTS. I. ACTION OF CYTOSINE ARABINOSIDE AND SOME COMPARISONS WITH 5-IODO-2-DEOXYURIDINE.

Authors:  D A BUTHALA
Journal:  Proc Soc Exp Biol Med       Date:  1964-01

3.  Herpesvirus hominis infection in newborn mice: comparison of the therapeutic efficacy of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyladenine.

Authors:  E R Kern; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

4.  Cytomegalovirus in the normal pregnant woman.

Authors:  R J Hildebrandt; J L Sever; A M Margileth; D A Callagan
Journal:  Am J Obstet Gynecol       Date:  1967-08-15       Impact factor: 8.661

5.  Congenital cytomegalovirus infection. Developmental progress of infants detected by routine screening.

Authors:  M E Melish; J B Hanshaw
Journal:  Am J Dis Child       Date:  1973-08

6.  Immunosuppression during acute murine cytomegalovirus infection.

Authors:  J E Osborn; A A Blazkovec; D L Walker
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

7.  Cytomegalovirus infection and cytomegalic inclusion disease in renal homotransplant recipients.

Authors:  R E Kanich; J E Craighead
Journal:  Am J Med       Date:  1966-06       Impact factor: 4.965

8.  Suppression of interferon and antibody and multiplication of Newcastle disease virus in cytomegalovirus infected mice.

Authors:  J E Osborn; D N Medearis
Journal:  Proc Soc Exp Biol Med       Date:  1967-02

9.  Sensitivity of Types 1 and 2 Herpes Simplex Virus to 5-Iodo-2'-Deoxyuridine and 9-beta-d-Arabinofuranosyladenine.

Authors:  D A Person; P J Sheridan; E C Herrmann
Journal:  Infect Immun       Date:  1970-12       Impact factor: 3.441

10.  Virulence and attenuation of murine cytomegalovirus.

Authors:  J E Osborn; D L Walker
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

View more
  12 in total

1.  Pyrimidinone (bropirimine) mediated alteration of T lymphocyte subsets during murine cytomegalovirus infection.

Authors:  R J Brideau; J A Nicholas
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

2.  Treatment of a murine cytomegalovirus infection with exogenous interferon, polyinosinic-polycytidylic acid, and polyinosinic-polycytidylic acid-poly-L-lysine complex.

Authors:  E R Kern; G A Olsen; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

3.  Alteration of host defense mechanisms by murine cytomegalovirus infection.

Authors:  D K Kelsey; G A Olsen; J C Overall; L A Glasgow
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

4.  Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate.

Authors:  E R Kern; L A Glasgow; J C Overall; J M Reno; J A Boezi
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

5.  Effect of pyrimidinone treatment on lethal and immunosuppressive murine cytomegalovirus infection.

Authors:  R J Brideau; J A Wolcott
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

6.  Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses.

Authors:  V R Freitas; D F Smee; M Chernow; R Boehme; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Evaluation of continuous cell lines in antiviral studies with murine cytomegalovirus.

Authors:  D F Smee; A Colletti; H A Alaghamandan; L B Allen
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

8.  Effect of ribavirin on murine cytomegalovirus infection.

Authors:  J N Dowling; B Postic; L O Guevarra
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

9.  Activity of trifluorothymidine against cytomegalovirus.

Authors:  J R Wingard; R K Stuart; R Saral; W H Burns
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

10.  Efficacy of acyclovir against mouse cytomegalovirus in vivo.

Authors:  J R Wingard; W J Bender; R Saral; W H Burns
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.